EXCLI J EXCLI Journal 1611-2156 Leibniz Research Centre for Working Environment and Human Factors 2013-622 Doc1020 Editorial material Improved genotyping of N-acetyltransferase 2: role of the ultra-slow acetylators Blaszkewicz Meinolf * 1 Leibniz Research Centre for Working Environment and Human Factors, Dortmund/Germany *To whom correspondence should be addressed: Meinolf Blaszkewicz, Leibniz Research Centre for Working Environment and Human Factors, Dortmund/Germany, E-mail: Blaszkewicz@ifado.de 05 12 2013 2013 12 1020 1023 04 12 2013 05 12 2013 Copyright © 2013 Blaszkewicz 2013

This is an Open Access article distributed under the following Assignment of Rights http://www.excli.de/documents/assignment_of_rights.pdf. You are free to copy, distribute and transmit the work, provided the original author and source are credited.

This article is available from http://www.excli.de/vol12/Blaszkewicz_05122013_proof.pdf


N-acetyltransferase 2 polymorphisms are of high relevance in clinical toxicology (Lück et al., 2009[29]; Bing et al., 2011[4]; Costa et al., 2012[9]). The slow acetylator genotype of NAT2 has been demonstrated to be associated with an increased risk of anti-tuberculosis drug-induced liver damage (Cai et al., 2012[7]; Lv et al., 2012[30]; An et al., 2012[2]; Ben Mahmoud et al., 2012[3]; Bose et al., 2011[6]). Moreover, many urinary bladder carcinogens are substrates of NAT2 (Golka et al., 1996[16]; 2002[15]; Vineis et al., 2001[44]; Hung et al., 2004[25]; Moore et al., 2011[31]). Large meta-analyses have clearly shown an association between slow acetylation genotypes and increased risk of bladder cancer (Garcia-Closas et al., 2005[14]; 2011[13]; Sanderson et al., 2007[34]; Agúndez et al., 2008[1]; Hein, 2002[20], 2006[21], 2009[22]; Hein and Doll, 2012[23][24]). However, at the level of individual studies the results remain controversial. Of 46 studies included into one of the recent meta-analysis 35 did not reach statistical significance (Moore et al., 2011[31]).

To clarify the situation a recent study has been performed to identify the role of 'extreme' genotypes (Selinski et al., 2013[36]). This study is based on a population of 344 individuals that have been phenotyped by the caffeine test (Blaszkewicz, 2004[5]; Hakooz, 2009[18]; Jetter et al., 2009[26]). This test quantitatively determines the activity of NAT2 in vivo. A subgroup with an `ultra-slow´ in vivo metabolism of caffeine was identified.

Interestingly, these individuals with the ultra-slow NAT2 phenotype carried several slow acetylator alleles and could be identified as *6A/*6A, *6A/*7B and *7B/*7B genotypes. This combination of slow alleles, the 'ultra-slow genotype' was further tested in 1,712 bladder cancer cases and 2,020 controls. Remarkably, individuals with the 'ultra-slow' genotype showed an increased odds ratio for bladder cancer risk (OR=1.31, P=0.012) whereas the slow acetylators in general were not significantly associated with cancer risk.

Currently, a huge number of studies is performed to understand the association between genetic variations and phenotype (Daly, 2013[10]; Stewart and Marchan, 2012[41]; Partosch et al., 2013[32]; Sobin et al., 2011[40]; Tumer et al., 2012[42]; Zeller et al., 2012[45]; Escobar-García et al., 2012[11]). A special focus are drug metabolizing enzymes and their role in carcinogenesis (Chen et al., 2012[8]; Hanioka et al., 2011[19]; Santovito et al., 2011[35]; Fujihara et al., 2011[12]; Lankisch et al., 2008[27]; Ulusoy et al., 2007[43]). Genome-wide association studies have identified to which degree genetic variants influence bladder cancer risk (Golka et al., 2011[17]; Selinski et al., 2011[37], 2012[38][39]; Safarinejad et al., 2011[33]; Lehmann et al., 2010[28]). However, most of these approaches considered only the genotype in relation to disease. The present study (Selinski et al., 2013[36]) demonstrates the importance of understanding the association of haplotypes with enzyme activity and the relevance of extreme phenotypes.

Agúndez JA Golka K Martínez C Selinski S Blaszkewicz M García-Martín E Unraveling ambiguous NAT2 genotyping data Clin Chem 2008 54 1390 1394 An HR Wu XQ Wang ZY Zhang JX Liang Y NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients Clin Exp Pharmacol Physiol 2012 39 535 543 Ben Mahmoud L Ghozzi H Kamoun A Hakim A Hachicha H Hammami S Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis Pathol Biol (Paris) 2012 60 324 330 Bing C Xiaomeia C Jinhenga L Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects Drug Metabol Drug Interact 2011 26 113 118 Blaszkewicz M Angerer J Müller M Weiss T N-Acetyltransferase 2 (phenotyping: caffeine test) Analyses of hazardous substances in biological materials, Vol 9. Special issue: Markers of susceptibility 2004 Weinheim Wiley-VCH 165 182 Bose PD Sarma MP Medhi S Das BC Husain SA Kar P Role of polymorphic N-acetyl transferase 2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis J Gastroenterol Hepatol 2011 26 312 318 Cai Y Yi J Zhou C Shen X Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis PLoS One 2012 7 10 e47769 Chen SC Chen CC Kuo CY Huang CH Lin CH Lu ZY Elevated risk of hypertension induced by arsenic exposure in Taiwanese rural residents: possible effects of manganese superoxide dismutase (MnSOD) and 8-oxoguanine DNA glycosylase (OGG1) genes Arch Toxicol 2012 86 869 878 Costa GN Magno LA Santana CV Konstantinovas C Saito ST Machado M Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs Mol Diagn Ther 2012 16 241 250 Daly AK Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms Arch Toxicol 2013 87 407 420 Escobar-García DM Del Razo LM Sanchez-Peña LC Mandeville PB Lopez-Campos C Escudero-Lourdes C Association of glutathione S-transferase Ω 1-1 polymorphisms (A140D and E208K) with the expression of interleukin-8 (IL-8), transforming growth factor beta (TGF-β), and apoptotic protease-activating factor 1 (Apaf-1) in humans chronically exposed to arsenic in drinking water Arch Toxicol 2012 86 857 868 Fujihara J Yasuda T Kato H Yuasa I Panduro A Kunito T Genetic variants associated with arsenic metabolism within human arsenic (+3 oxidation state) methyltransferase show wide variation across multiple populations Arch Toxicol 2011 85 119 125 García-Closas M Hein DW Silverman D Malats N Yeager M Jacobs K A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background Pharmacogenet Genomics 2011 21 231 236 García-Closas M Malats N Silverman D Dosemeci M Kogevinas M Hein DW NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses Lancet 2005 366 9486 649 659 Golka K Prior V Blaszkewicz M Bolt HM The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences Toxicol Lett 2002 128 229 241 Golka K Prior V Blaszkewicz M Cascorbi I Schöps W Kierfeld G Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany Scand J Work Environ Health 1996 22 332 338 Golka K Selinski S Lehmann ML Blaszkewicz M Marchan R Ickstadt K Genetic variants in urinary bladder cancer: collective power of the "wimp SNPs" Arch Toxicol 2011 85 539 554 Hakooz NM Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities Curr Drug Metab 2009 10 329 338 Hanioka N Oka H Nagaoka K Ikushiro S Narimatsu S Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation Arch Toxicol 2011 85 1373 1381 Hein DW Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis Mutat Re 2002 506-507 65 77 Hein DW N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk Oncogene 2006 25 1649 1658 Hein DW N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine Expert Opin Drug Metab Toxicol 2009 5 353 366 Hein DW Doll MA A four-SNP NAT2 genotyping panel recommended to infer human acetylator phenotype Pharmacogenomics 2012 13 855 Hein DW Doll MA Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes Pharmacogenomics 2012 13 31 41 Hung RJ Boffetta P Brennan P Malaveille C Hautefeuille A Donato F GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population Int J Cancer 2004 110 598 604 Jetter A Kinzig M Rodamer M Tomalik-Scharte D Sörgel F Fuhr U Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected? Eur J Clin Pharmacol 2009 65 411 417 Lankisch TO Gillman TC Erichsen TJ Ehmer U Kalthoff S Freiberg N Aryl hydrocarbon receptor-mediated regulation of the human estrogen and bile acid UDP-glucuronosyltransferase 1A3 gene Arch Toxicol 2008 82 573 582 Lehmann ML Selinski S Blaszkewicz M Orlich M Ovsiannikov D Moormann O Rs710521 A on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk Arch Toxicol 2010 84 967 978 Lück H Kinzig M Jetter A Fuhr U Sörgel Mesalazine pharmacokinetics and NAT2 phenotype Eur J Clin Pharmacol 2009 65 47 54 Lv X Tang S Xia Y Zhang Y Wu S Yang Z NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population Ann Hepatol 2012 11 700 707 Moore LE Baris DR Figueroa JD Garcia-Closas M Karagas MR Schwenn MR GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis Carcinogenesis 2011 32 182 189 Partosch F Mielke H Gundert-Remy U Functional UDP-glucuronyltransferase 2B15 polymorphism and bisphenol A concentrations in blood: results from physiologically based kinetic modelling Arch Toxicol 2013 87 1257 1264 Safarinejad MR Shafiei N Safarinejad SH The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) gene Arch Toxicol 2011 85 1209 1218 Sanderson S Salanti G Higgins J Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis Am J Epidemiol 2007 166 741 751 Santovito A Schilirò T Castellano S Cervella P Bigatti MP Gilli G Combined analysis of chromosomal aberrations and glutathione S-transferase M1 and T1 polymorphisms in pathologists occupationally exposed to formaldehyde Arch Toxicol 2011 85 1295 1302 Selinski S Blaszkewicz M Ickstadt K Hengstler JG Golka K Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk Arch Toxicol 2013 87 2129 2139 Selinski S Blaszkewicz M Lehmann ML Ovsiannikov D Moormann O Guballa C Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype Pharmacogenet Genomics 2011 21 673 678 Selinski S Lehmann ML Blaszkewicz M Ovsiannikov D Moormann O Guballa C Rs11892031 A on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk Arch Toxicol 2012 86 1369 1378 Selinski S Lehmann ML Blaszkewicz M Ovsiannikov D Moormann O Guballa C Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene Arch Toxicol 2012 86 195 203 Sobin C Parisi N Schaub T Gutierrez M Ortega AX δ-Aminolevulinic acid dehydratase single nucleotide polymorphism 2 and peptide transporter 2*2 haplotype may differentially mediate lead exposure in male children Arch Environ Contam Toxicol 2011 61 521 529 Stewart JD Marchan R Polymorphisms hit the headlines Arch Toxicol 2012 86 1799 1801 Tumer TB Sahin G Arinç E Association between polymorphisms of EPHX1 and XRCC1 genes and the risk of childhood acute lymphoblastic leukemia Arch Toxicol 2012 86 431 439 Ulusoy G Arinç E Adali O Genotype and allele frequencies of polymorphic CYP2E1 in the Turkish population Arch Toxicol 2007 81 711 718 Vineis P Marinelli D Autrup H Brockmoller J Cascorbi I Daly AK Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies Cancer Epidemiol Biomarkers Prev 2001 10 1249 1252 Zeller J Högel J Linsenmeyer R Teller C Speit G Investigations of potential susceptibility toward formaldehyde-induced genotoxicity Arch Toxicol 2012 86 1465 1473